What is it about?
Estimation of the use of intermittent androgen deprivation (IAD) therapy based on all the electronic prescriptions available in one area in order to improve the quality of life of prostate cancer (PC) patients without affecting their expected overall survival.
Featured Image
Why is it important?
Significant improvement of patient's quality of life together with important savings for the Health System could be achieved using IAD therapy in some PC patients. The proposed estimation method of IAD use will give you a picture of the current situation in your area and identify some potential room for maneuver.
Perspectives
Given the large potential clinical and economic benefits that greater use of IAD could provide, future studies are needed to confirm these findings and to identify new strategies to increase the use of IAD.
Dr. José Antonio Cordero
Fundacio Blanquerna Universitat Ramon Llull
Read the Original
This page is a summary of: Population-based estimate of the use of intermittent androgen deprivation therapy in prostate cancer patients in Catalonia, Spain, Pharmacoepidemiology and Drug Safety, March 2019, Wiley,
DOI: 10.1002/pds.4744.
You can read the full text:
Contributors
The following have contributed to this page
